Verrica Pharmaceuticals Inc

NASDAQ:VRCA   1:24:43 PM EDT
13.02
+0.19 (+1.48%)
Products

Verrica Pharmaceuticals Receives CRL From FDA On New Drug Application For VP-102

Published: 09/20/2021 20:42 GMT
Verrica Pharmaceuticals Inc (VRCA) - Verrica Pharmaceuticals Receives Complete Response Letter From the FDA Identifying Deficiencies at a Facility of a Contract Manufacturer for Its New Drug Application for Vp-102 for the Treatment of Molluscum Contagiosum.
Verrica Pharmaceuticals Inc - No Clinical, Safety Or Cmc Issues Specific to Vp-102 Identified.
Verrica Pharmaceuticals Inc - According to Crl, FDA Has Identified Deficiencies at a Facility of a Contract Manufacturing Organization.